Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MF59-adjuvanted H5N6 cell culture-derived influenza vaccine
- Development stage
- Phase 2
- Lead developer
- CSL Seqirus
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MF59-adjuvanted H5N6 cell culture-derived influenza vaccine (aH5N6c) is an inactivated vaccine developed for immunization against influenza A H5N6 virus. It is formulated with the MF59 adjuvant to enhance immune response. The vaccine is being studied in various priming and booster regimens, including as a heterologous booster following H5N1 vaccination. Clinical trials have evaluated its safety and immunogenicity in both adult (18-64 years) and elderly (≥65 years) populations.
- Other names
- Influenza A virus H5N6 vaccine
02
Targets
H5 HA (Influenza A hemagglutinin H5)
Beyond the preview
Go deeper on MF59-adjuvanted H5N6 cell culture-derived influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MF59-adjuvanted H5N6 cell culture-derived influenza vaccine.